TRADING UPDATES: essensys loss widens; Carclo demand strong
18th Oct 2022 22:04
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Open Orphan PLC - London-based research organisation testing infectious and respiratory disease products - Confirms that it is helping the relevant Irish authorities with an allegation of potential insider trading dealing in the company's shares in 2020. Open Orphan says trading in the company's shares was undertaken by an "unconnected private individual". It said "there are no implications for the company in the resolution of this allegation and confirms that no employee, executive, director or anyone connected with the company had any involvement whatsoever in this matter nor are they suspected of any wrongdoing." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Open Orphan PLC on Monday said its subsidiary hVIVO Ltd has won a GBP10.4 million contract. Read More
Open Orphan PLC - London-based pharmaceutical services - Signs a GBP6.2 million contract with an unnamed US-based biotech firm to test its antiviral candidate using the hVIVO influenza A human challenge study model. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Open Orphan PLC on Tuesday said its subsidiary hVIVO Ltd has won a GBP7.2 million contract, marking the company's third win since May 18. Read More
Open Orphan PLC - London-based pharmaceutical services - Swings to pretax profit of GBP277,000 in 202, from a loss of GBP11.0 million. Revenue rises 74% to GBP39.0 million from GBP22.2 million. Attributes growth to a record number of human challenge study contracts won throughout year. Order book grows 11% to GBP46 million of future contracted revenue as at December 31 from GBP41.6 million, year-on-year. Order book stands at GBP64.2 million on June 1. Says the revenue is expected to be recognised across 2022, 2023 and 2024. Confident in further growth in 2022. Looks forward to "converting its progress into value for shareholders." Read More
(Alliance News) - Open Orphan PLC on Wednesday said it's subsidiary hVIVO signed a GBP14.7 million contract for an influenza characterisation study and a follow on influenza human challenge study. Read More
(Alliance News) - Open Orphan PLC on Wednesday said its subsidiary hVIVO Ltd has signed a GBP7.3 million contract. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Open Orphan PLC - London-based pharmaceutical services - Subsidiary hVIVO is awarded new study with existing unnamed pharmacetical client to act as vaccination site for the client's respiratory syncytial virus vaccine candidate. hVIVO's specialist arm FluCamp will recruit 60 healthy volunteers to the new site clinic at Plumbers Row where trials will take place. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Open Orphan PLC - London-based pharmaceutical services - Says Thursday that results from the world's first Covid-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. Says study showed the SARS-CoV-2 human challenge was safe in healthy young adults and provided insights into the course of Covid-19 infection with potential positive public health implications. With the characterisation study disease modelling data completed, and human challenge model established, Open Orphan says it should be able to conduct Covid-19 human challenge studies in 2022. Read More